Vertex Pharmaceuticals, Inc. (VRTX)
ROA
Obliczenia
|
2022/Q4 (31 gru 2022) |
2022/Q3 (30 wrz 2022) |
2022/Q2 (30 cze 2022) |
2022/Q1 (31 mar 2022) |
2021/Q4 (31 gru 2021) |
2021/Q3 (30 wrz 2021) |
2021/Q2 (30 cze 2021) |
2021/Q1 (31 mar 2021) |
||
|---|---|---|---|---|---|---|---|---|---|
| Zysk netto (ttm) | w tys. USD | 3 322 000 | 4 043 320 | 3 964 748 | 3 221 172 | 4 684 200 | 2 176 180 | 1 991 686 | 2 762 032 |
| Aktywa razem | w tys. USD | 18 150 900 | 16 706 400 | 15 582 200 | 14 256 100 | 26 865 000 | 12 618 700 | 12 221 700 | 12 115 100 |
| ROA | 18,30% | 24,20% | 25,44% | 22,60% | 17,44% | 17,25% | 16,30% | 22,80% |
2022/Q4 obliczenia
ROA = Zysk netto (ttm) ÷ Aktywa razem
= $3 322 000K ÷ $18 150 900K
= 18,30%
Analiza porównawcza
2022/Q4
Nazwa spółki
Symbol
ROA
Vertex Pharmaceuticals, Inc.
VRTX
18,30%
Bristol-Myers Squibb Co.
BMY
6,53%
Catalent Inc.
CTLT
3,65%
Cytokinetics Inc
CYTK
-38,33%
Jazz Pharmaceuticals plc
JAZZ
-2,07%
Organon & Co.
OGN
8,37%
Perrigo Company plc
PRGO
-1,28%
Regeneron Pharmaceuticals, Inc.
REGN
14,85%
United Therapeutics Corp
UTHR
12,03%
Viatris Inc
VTRS
4,16%
Zoetis Inc
ZTS
14,16%